Outcomes of 54 cases of monkeypox (MPX) in London: fewer early symptoms but higher rates of genital lesions – urgency of funding sexual health

Featured HTB July 2022 (1 July 2022) now online

Introduction to ART: i-Base guide (June 2022)

Sending unused meds to Ukraine: emergency appeal

Organisations to support Ukraine

Monkeypox crisis in the UK needs urgent funding: sex, vaccines and Pride

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): final report

CROI 2022: NAMSAL study comparing DTG to EFV400 in Cameroon: week 192 results

Lenacapavir gets positive opinion for approval in the EU to treat MDR HIV

Combination bNAb’s sustain viral suppression for 40 weeks: phase 1 results

Dual bNAbs in children: dose-finding and safety data on VRC01LS and 10-1074 in the Tatelo study 

UK offers limited vaccine to gay and bisexual men at risk of monkeypox: full dose offered in NYC

Full results from ANCHOR study published in NEJM

INSTIs and cardiovascular events in the RESPOND cohort: early increase at six months normalises after two years

Gonorrhoea vaccine might halve infections and help combat drug resistance

COVID update: new waves of BA.4 and BA.5 in the UK – all omicron variants linked to reduced antibody responses to vaccines

Importance of booster vaccine to protect against emergent COVID-19 variants

Similar COVID-19 vaccination responses in HIV positive people on ART and with good CD4 counts compared to HIV negative controls

US study reports higher rates of breakthrough COVID in HIV positive vs negative controls

BMJ reports UK government failed to protect doctors during COVID-19

Fantastic voyage: tracking adherence sensors in PrEP meds

UK increases funding to UNAIDS: still dramatically lower than before last years’ 80% cut

Future meetings and webinars 2022

HTB: no. 7 (1 July 2022) PDF downloads

HTB June 2022 (1 June 2022)

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): further reports

CROI 2022: Updates from the VESTED study

CROI 2022: Switching to dolutegravir for adults on stable PI-based second-line ART

Lenacapavir in MDR HIV: phase 3 results of CAPELLA study published

ViiV licenses long-acting cabotegravir (CAB-LA) for generic access

Monkeypox outbreak: Update and further information

Draft BHIVA guidelines online for comment: deadline 9 June

Monkeypox cases in gay men in the UK: BHIVA and ECDC rapid statements

Monkeypox DNA in semen supports advice to use condoms for eight weeks after infection has cleared

Risk of monkeypox becoming endemic in Europe: ECDC assessment

Seven cases of monkeypox virus in the UK from 2018 to 2021

Monkeypox: Q&A factsheet

Implications of SARS-CoV-2 in gut tissue for transmission of COVID-19 and long COVID

HTB: no. 6 (1 June 2022) PDF downloads

Family of Greek activist Zak Kostopoulos decry minimal sentence given to his killers

Featured HTB May 2022 (2 May 2022)

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports

CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART

CROI 2022: Other COVID-19 studies

FDA approves dispersible dolutegravir/abacavir/3TC for children

Access to ibalizumab uncertain in Europe: TaiMed looking for new partner after Thera quits

Asymptomatic COVID-19 is common in people living with HIV

Longest COVID-19 infection lasted 505 days in an immunocompromised person in London

Herd immunity unlikely to control COVID-19: opinion article from US NIAID

The challenges of prioritising access to molnupiravir and nirmatrelvir–ritonavir for COVID-19

Increased risk of blood clots after COVID-19: higher with underlying conditions and more severe symptoms

Two new platform vaccines against COVID-19 report phase 3 results

A&E adopts opt-out HIV testing in London, Manchester, Salford and Brighton

Zimbabwe decriminalises HIV transmission

Community webinar series on HIV cure-related cell and gene therapy

HTB: no. 5 (2 May 2022) PDF downloads

HTB April 2022 (1 April 2022)

29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports

CROI 2022: Webcasts now online and open access

CROI 2022: Islatravir studies for HIV treatment and PrEP

CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART

CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa

CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses

CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART

CROI 2022: UK study shows PEP is started earlier using home starter packs

Post navigation